Lyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent Delisting

Lyra Therapeutics ( (LYRA) ) just unveiled an update.

On March 13, 2026, Lyra Therapeutics, Inc. disclosed that it received confirmation from Nasdaq that the company has withdrawn its appeal of a February 2, 2026 delisting determination. As a result of this withdrawal, trading in Lyra’s common stock is scheduled to be suspended at the open of trading on Tuesday, March 17, 2026, with Nasdaq to proceed toward formally delisting the shares, signaling a significant setback for the company’s public-market presence and raising concerns for shareholders’ liquidity and valuation.

The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Spark’s Take on LYRA Stock

According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.

The score is driven primarily by weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (price well below key moving averages with negative MACD). A highly negative corporate event (program halt, near-total workforce reduction, leadership changes, and strategic-alternatives process) adds material risk, while valuation metrics offer limited support due to ongoing losses and no dividend.

To see Spark’s full report on LYRA stock, click here.

More about Lyra Therapeutics

Lyra Therapeutics, Inc. is a biopharmaceutical company that develops therapies using proprietary drug delivery platforms for ear, nose and throat disorders. Its primary products and candidates target chronic rhinosinusitis and related inflammatory conditions, focusing on patients who are insufficiently served by existing medical and surgical options in the U.S. market.

Average Trading Volume: 80,334

Technical Sentiment Signal: Sell

Current Market Cap: $2.34M

Learn more about LYRA stock on TipRanks’ Stock Analysis page.